Not to be used for the treatment of pregnant mares.

Do not use in horses with severe hepatic impairment.

Buildings occupied by infected animals should be thoroughly cleaned and disinfected; all equipment used during the treatment should also be cleaned and disinfected. These measures will minimise risk of infection. Mix thoroughly with the total feed ration so that the required dose is contained in the amount each animal will consume at one feed. Add to feed immediately prior to administration. Discard any remaining medicated feed.

May be used for the treatment of groups of animals or for individuals. For dosing, animals should be approximately equal in bodyweight. Adequate trough space should be available and shy feeders should be fed individually to ensure adequate dosage.

Prophylactic therapy is advised for in-contact animals only. The normal 7-day course is recommended.

Keep horses away from infected cattle.

Do not use in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

When handling this product or feed containing the product, wear impervious gloves and either a half-mask respirator conforming to European Standard EN149 or a non-disposable respirator conforming to European Standard EN140 with filter to EN143.

The product or feed containing the product must not be handled by women of childbearing potential.

Long-term administration of high doses of griseofulvin with feed has been reported to be hepatotoxic in cats and to induce hepatomas in mice and thyroid tumours in rats but not in hamsters. The clinical significance of these findings for man or the target species is not known. Griseofulvin may be teratogenic.

Not to be used for the treatment of pregnant mares. It can be safely administered to lactating animals.